Beta-Cell Regeneration
Regrow the insulin-producing cells that diabetes destroys
The goal is to regrow the body’s own insulin-producing beta cells — the cells the immune system destroys in type 1 diabetes — so that a person whose body can no longer make insulin can make it again. Not a better injection. The return of the body’s own insulin, from living cells, regulating blood sugar in real time.
In type 1 diabetes, the immune system destroys the beta cells in the pancreas that make insulin, and the body loses the ability to control its own blood sugar — forcing a lifetime of insulin injections that, however careful, never match the moment-to-moment precision of living cells. The consequences of imperfect control are severe and lifelong. Regrowing functional beta cells would do something injections never can: restore the body’s own automatic blood-sugar control. This is the flagship of metabolic health because it is the difference between managing diabetes forever and reversing it at its source.
We are building the capability to produce, deliver, and protect new insulin-producing cells that behave like the originals: sensing glucose and secreting exactly the right insulin, second by second, integrated into the body — and surviving long-term without being destroyed again by the immune system. The destination is a person with type 1 diabetes living insulin-independent because their body makes its own insulin again.
Making, delivering, and protecting new beta cells
Growing beta cells from stem cells Clinical — Phase 3
Scientists turn stem cells into fully differentiated, glucose-responsive islet cells in the lab. Infused into patients, these cells make insulin on their own — and this therapy is now in Phase 3 trials.
Restoring real-time control Demonstrated
The regrown cells are living sensors: they read blood glucose and release insulin moment to moment, restoring the biological feedback loop injections cannot replicate.
Protecting cells from the immune attack Frontier
Because type 1 diabetes is autoimmune, transplanted cells are attacked. Gene-edited hypoimmune cells and protective encapsulation aim to let new cells survive without lifelong immunosuppression.
Regenerating cells from within Frontier
Beyond transplant, researchers are exploring prompting the pancreas to regenerate its own beta cells — restoring the source itself.
Cited as evidence the capability is real — not as partners or endorsers.
Companies & clinical programs
Vertex Pharmaceuticals (stem-cell-derived islet therapy in Phase 3) building on the Melton-lab differentiation protocol from Harvard; islet-engineering and gene-editing programs.
Government & programs
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, NIH) · the FDA, which approved the first cellular therapy for type 1 diabetes · NIH regenerative-medicine programs.
Enabling science base
stem-cell-derived islet cells · beta-cell differentiation protocols · gene-edited hypoimmune cells · cell encapsulation · autoimmune-tolerance research.
The core technologies: stem-cell differentiation that reliably turns pluripotent stem cells into working islet cells; islet manufacturing at clinical scale; gene editing to create hypoimmune cells the immune system ignores; encapsulation that shields cells while letting glucose and insulin pass; and immune-tolerance approaches that aim to stop the original autoimmune attack.
Insulin independence in trial patients Clinical
In a clinical trial, patients with type 1 diabetes who received stem-cell-derived islet cells achieved insulin independence — their bodies made and regulated their own insulin again.
Advanced to Phase 3 Clinical — Phase 3
The therapy has progressed to a Phase 3 trial enrolling around fifty patients, the final stage before potential approval — described as a first scalable potential cure for type 1 diabetes.
First FDA cell therapy for T1D Clinical
A donor-islet cell therapy became the first FDA-approved cellular treatment for type 1 diabetes — establishing that replacing islet cells can free patients from insulin.
Toward no immunosuppression Frontier
Gene-edited hypoimmune islet cells are being developed so future patients could receive new cells without lifelong immune-suppressing drugs.
The honest remaining challenges: today’s therapy requires immune-suppressing medication to protect the transplanted cells — a real trade-off the next generation (hypoimmune cells, encapsulation) aims to remove. Durability: cells must keep working for many years. Scale and access: manufacturing enough cells for millions is a major task. And stopping the autoimmune cause itself — so the body doesn’t attack new cells the way it attacked the originals — remains the deepest challenge. The capability is real and in Phase 3; it is not yet a finished, universal cure, and we say so.
The future, fully built
A person with type 1 diabetes — who lived tethered to injections and the fear of every high and low — has their insulin-producing cells regrown: blood sugar regulated automatically by living cells again, insulin independence restored, the condition reversed at its biological source, without trading it for a lifetime of immunosuppression. Making insulin becomes something the body does for itself again.
The proof, for this capability
Cited as evidence the capability is real, not as partners or endorsers.
Stem-cell-derived islet therapy (Phase 3)
Patients achieved insulin independence in trials; the therapy (Vertex, building on the Harvard Melton-lab protocol) is now in a Phase 3 trial of ~50 patients. Stage: Clinical (Phase 3).
First FDA-approved cell therapy for T1D
A donor-islet cellular therapy became the first FDA-approved cell treatment for type 1 diabetes. Stage: Clinical (approved).
Hypoimmune gene-edited islets
Gene-edited islet cells designed to evade immune attack aim to remove the need for immunosuppression. Stage: Frontier.
Honest framing
Real organizations and studies are cited as evidence the capability is real — not as partners or endorsers. Current therapy needs immunosuppression; we do not present a universal cure as finished.
Help build this future
Every signature grows the movement to make beta-cell regeneration real — and free at the point of need.